Drug Search Results
More Filters [+]

MK-0493

Alternative Names: mk-0493, mk0493, mk 0493
Latest Update: 2022-03-01
Latest Update Note: News Article

Product Description

MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19741604/)

Mechanisms of Action: MCR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-0493

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00482196

P2

Completed

Obesity

2006-03-01

NCT00482638

P2

Completed

Obesity

2004-10-29

Recent News Events